Colorectal cancer is one of the main causes of cancer death worldwide, and novel biomarkers are urgently needed for its early diagnosis and treatment.
The utilization of metabolomics to identify and quantify metabolites in body fluids may allow the detection of changes in their concentrations that could serve as diagnostic markers for colorectal cancer and may also represent new therapeutic targets. Metabolomics generates a pathophysiological 'fingerprint' that is unique to each individual. The purpose of our study was to identify a differential metabolomic signature for metastatic colorectal cancer.
This study has been developed by a multidisciplinary team of scientists from the Department of Anatomy and Embryology of the University of Granada, Fundación MEDINA and members of the Service of Medical Oncology of University Hospital Virgen de las Nieves of Granada.
